Amgen Inc. $AMGN Shares Sold by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 15.2% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 19,065 shares of the medical research company’s stock after selling 3,430 shares during the period. E. Ohman J or Asset Management AB’s holdings in Amgen were worth $6,240,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Avanza Fonder AB boosted its position in shares of Amgen by 12.5% during the 4th quarter. Avanza Fonder AB now owns 64,357 shares of the medical research company’s stock worth $21,065,000 after purchasing an additional 7,150 shares in the last quarter. Salem Investment Counselors Inc. increased its holdings in shares of Amgen by 3.5% in the 4th quarter. Salem Investment Counselors Inc. now owns 29,934 shares of the medical research company’s stock valued at $9,798,000 after purchasing an additional 1,016 shares in the last quarter. Rialto Wealth Management LLC lifted its stake in shares of Amgen by 11.5% in the fourth quarter. Rialto Wealth Management LLC now owns 3,307 shares of the medical research company’s stock valued at $1,082,000 after purchasing an additional 340 shares during the period. Sunflower Bank N.A. boosted its holdings in Amgen by 7.2% during the fourth quarter. Sunflower Bank N.A. now owns 951 shares of the medical research company’s stock worth $311,000 after buying an additional 64 shares in the last quarter. Finally, Somerset Trust Co boosted its holdings in Amgen by 1.4% during the fourth quarter. Somerset Trust Co now owns 20,873 shares of the medical research company’s stock worth $6,832,000 after buying an additional 281 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AMGN. UBS Group increased their target price on shares of Amgen from $380.00 to $390.00 and gave the company a “buy” rating in a report on Monday, January 26th. Freedom Capital cut shares of Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. Daiwa Securities Group increased their price target on shares of Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. Argus lifted their price objective on Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Finally, Jefferies Financial Group started coverage on Amgen in a research note on Tuesday, March 10th. They issued a “hold” rating and a $350.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $354.60.

Amgen Trading Up 0.6%

Shares of Amgen stock opened at $349.77 on Tuesday. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $391.29. The business’s fifty day moving average is $360.77 and its two-hundred day moving average is $328.60. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The firm has a market cap of $188.55 billion, a PE ratio of 24.58, a P/E/G ratio of 3.45 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the previous year, the business earned $5.31 earnings per share. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is presently 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.